ARID1A alterations in gastrointestinal cancers as therapeutic opportunities.

被引：1
|
作者：
Basu, Gargi D.
White, Tracey
LoBello, Janine R.
Lau, Kevin R.
Syring, Michael
Krishnan, Subha
Gonzalez, Laura
Royce, Thomas
Kurdoglu, Ahmet
Halbert, Matthew J.
Kiefer, Jeff
Cherni, Irene
Aldrich, Jessica
Izatt, Tyler
Russell, Megan
Nasser, Sara
Carpten, John D.
Craig, David W.
Demeure, Michael J.
机构：
[1] Ash Analyt LLC, Phoenix, AZ USA
[2] Ash Analyt, Phoenix, AZ USA
[3] Translat Genom Res Inst, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.671
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
671
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ARID1A alterations in gynecological cancers as a therapeutic opportunity.
    Gonzalez-Malerva, Laura
    Basu, Gargi D.
    Syring, Michael
    Krishnan, Subha
    White, Tracey
    LoBello, Janine R.
    Lau, Kevin R.
    Royce, Thomas
    Kurdoglu, Ahmet
    Demeure, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] ARID1A in Gynecologic Precancers and Cancers
    Morgan, Jaida E.
    Jaferi, Nishah
    Shonibare, Zainab
    Huang, Gloria S.
    [J]. REPRODUCTIVE SCIENCES, 2024, 31 (08) : 2150 - 2162
  • [3] Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
    Khalique, Saira
    Naidoo, Kalnisha
    Attygalle, Ayoma D.
    Kriplani, Divya
    Daley, Frances
    Lowe, Anne
    Campbell, James
    Jones, Thomas
    Hubank, Michael
    Fenwick, Kerry
    Matthews, Nicholas
    Rust, Alistair G.
    Lord, Christopher J.
    Banerjee, Susana
    Natrajan, Rachael
    [J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2018, 4 (03): : 154 - 166
  • [4] ARID1A alterations and their clinical significance in cholangiocarcinoma
    Namjan, Achira
    Techasen, Anchalee
    Loilome, Watcharin
    Sa-ngairnwibool, Prakasit
    Jusakul, Apinya
    [J]. PEERJ, 2020, 8
  • [5] ARID1A gene mutation in ovarian and endometrial cancers
    Takeda, Takashi
    Banno, Kouji
    Okawa, Ryuichiro
    Yanokura, Megumi
    Iijima, Moito
    Irie-Kunitomi, Haruko
    Nakamura, Kanako
    Iida, Miho
    Adachi, Masataka
    Umene, Kiyoko
    Nogami, Yuya
    Masuda, Kenta
    Kobayashi, Yusuke
    Tominaga, Eiichiro
    Aoki, Daisuke
    [J]. ONCOLOGY REPORTS, 2016, 35 (02) : 607 - 613
  • [6] Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations
    King, Gentry Teng
    Berg, Rachel
    Yilma, Binyam
    Stoppler, Melissa Conrad
    Hsieh, Ronan Wenhan
    Safyan, Rachael A.
    Zhen, David Bing
    Coveler, Andrew L.
    Cohen, Stacey A.
    Shankaran, Veena
    Chiorean, E. Gabriela
    Harris, William Proctor
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 557 - 557
  • [7] ARID1A Alterations and Their Clinical Significance in Breast Cancer
    Pimienta, Luisana Molina
    Sanchez, Juan Camilo Salgado
    Hernandez, Ingrid
    [J]. UNIVERSITAS MEDICA, 2023, 64 (01): : 1 - 11
  • [8] Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
    Tessiri, Supharada
    Techasen, Anchalee
    Kongpetch, Sarinya
    Namjan, Achira
    Loilome, Watcharin
    Chan-On, Waraporn
    Thanan, Raynoo
    Jusakul, Apinya
    [J]. PEERJ, 2022, 10
  • [9] The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
    Kwan, Suet-Yan
    Izaguirre, Daisy I.
    Cheng, Xuanjin
    Kwan, Suet-Ying
    Tsang, Yvonne T. M.
    Kwan, Hoi-Shan
    Wong, Kwong-Kwok
    [J]. CANCER RESEARCH, 2015, 75
  • [10] Therapeutic significance of ARID1A mutation in bladder cancer
    Conde, Marina
    Frew, Ian J.
    [J]. NEOPLASIA, 2022, 31
12345